Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1

Molecular and Cellular Biochemistry

Volumn 411, Issue 1-2, 2016, Pages 11-21

  Pathak, Bhakti R ^a   Breed, Ananya A ^a   Apte, Snehal ^a   Acharya, Kshitish ^b,c   Mahale, Smita D ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN REPRODUCTIVE HEALTH   (India)

^b Institute of Bioinformatics and Applied Biotechnology   (India)

^c Pvt Ltd   (India)

Author keywords

ANXA1; CRISP 3; Prognosis; Prostate cancer; PSA; shRNA

Indexed keywords

CYSTEINE RICH SECRETORY PROTEIN 3; KALLIKREIN; KALLIKREIN 3; LIPOCORTIN 1; PROSTATE SPECIFIC ANTIGEN; SECRETORY PROTEIN; UNCLASSIFIED DRUG; CRISP3 PROTEIN, HUMAN; SALIVA PROTEIN; SEMINAL PLASMA PROTEIN;

ARTICLE; CELL ADHESION; CELL INVASION; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; ION TRANSPORT; MICROARRAY ANALYSIS; PROSTATE CANCER; PROTEIN FUNCTION; UPREGULATION; VALIDATION PROCESS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION; VALIDATION STUDY;

ANNEXIN A1; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALIVARY PROTEINS AND PEPTIDES; SEMINAL PLASMA PROTEINS;

EID: 84957441833     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2564-2     Document Type: Article

References (34)

1. Obort AS, Ajadi MB, Akinloye O (2013) Prostate-specific antigen: any successor in sight? Rev Urol 15:97–107
2. Kosari F, Asmann YW, Cheville JC, Vasmatzis G (2002) Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 11:1419–1426
3. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW et al (2007) Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 13:4130–4138
4. Dahlman A, Edsjö A, Halldén C, Persson JL, Fine SW, Lilja H et al (2010) Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis 13:369–375. doi:10.1038/pcan.2010.25
5. Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A et al (2013) Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol 26:733–742. doi:10.1038/modpathol.2012.206
6. Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA (2014) Cysteine-rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosis. J Hematol Oncol 7:7–21. doi:10.1186/1756-8722-7-21
7. Gibbs GM, Roelants K, O’Bryan MK (2008) The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins—roles in reproduction, cancer, and immune defense. Endocr Rev 7:865–897. doi:10.1210/er.2008-0032
8. Krätzschmar J, Haendler B, Eberspaecher U, Roosterman D, Donner P, Schleuning WD (1996) The human cysteine-rich secretary protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3. Eur J Biochem 236:827–836
9. Kjeldsen L, Cowland JB, Johnsen AH, Borregaard N (1996) SGP28, a novel matrix glycoprotein in specific granules of human neutrophils with similarity to a human testis-specific gene product and a rodent sperm-coating glycoprotein. FEBS Lett 380:246–250
10. Niderman T, Genetet I, Bruyère T, Gees R, Stintzi A, Legrand M et al (1995) Pathogenesis-related PR-1 proteins are antifungal. Isolation and characterization of three 14-kilodalton proteins of tomato and of a basic PR-1 of tobacco with inhibitory activity against Phytophthora infestans. Plant Physiol 108:17–27
11. Lee U, Nam YR, Ye JS, Lee KJ, Kim N, Joo CH (2014) Cysteine-rich secretory protein 3 inhibits hepatitis C virus at the initial phase of infection. Biochem Biophys Res Commun 450:1076–1082. doi:10.1016/j.bbrc.2014.06.106
12. Brown RL, Lynch LL, Haley TL, Arsanjani R (2003) Pseudechetoxin binds to the pore turret of cyclic nucleotide-gated ion channels. J Gen Physiol 122:749–760
13. 2+ signaling. J Biol Chem 281:4156–4163
14. Udby L, Lundwall A, Johnsen AH, Fernlund P, Valtonen-André C, Blom AM et al (2005) beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun 333:555–561
15. Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M et al (2006) A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 175:1291–1297
16. Pathak BR, Breed AA, Nakhawa VH, Jagtap DD, Mahale SD (2010) Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific. Asian J Androl 12:677–689. doi:10.1038/aja.2010.56
17. Perretti M, D’Acquisto F (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9:62–70. doi:10.1038/nri2470
18. Bjartell A, Johansson R, Björk T, Gadaleanu V, Lundwall A, Lilja H et al (2006) Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 66:591–603
19. Balk SP, Ko YJ, Bubley GJ (2003) Biology of prostate-specific antigen. J Clin Oncol 21:383–391
20. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R (1989) The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141:873–879
21. Banefelt J, Liede A, Mesterton J, Stålhammar J, Hernandez RK, Sobocki P et al (2014) Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden. Cancer Epidemiol 38:442–447. doi:10.1016/j.canep.2014.04.007
22. Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V et al (2014) Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev 40:3–11. doi:10.1016/j.ctrv.2013.07.001
23. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C et al (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541–1550
24. Koivisto PA, Helin HJ (1999) Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J Pathol 189:219–223
25. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW (2000) Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 275:40846–40855
26. Webber MM, Waghray A, Bello D (1995) Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1:1089–1094
27. Cumming AP, Hopmans SN, Vukmirović-Popović S, Duivenvoorden WC (2011) PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo. Prostate Cancer Prostatic Dis 14:286–294. doi:10.1038/pcan.2011.34
28. Lim LH, Pervaiz S (2007) Annexin 1: the new face of an old molecule. FASEB J 21:968–975
29. Christmas P, Callaway J, Fallon J, Jones J, Haigler HT (1991) Selective secretion of annexin 1, a protein without a signal sequence, by the human prostate gland. J Biol Chem 266:2499–2507
30. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS et al (2000) Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 60:6293–6297
31. Patton KT, Chen HM, Joseph L, Yang XJ (2005) Decreased annexin I expression in prostatic adenocarcinoma and in high-grade prostatic intraepithelial neoplasia. Histopathology 47:597–601
32. Maschler S, Gebeshuber CA, Wiedemann EM, Alacakaptan M, Schreiber M, Custic I et al (2010) Annexin A1 attenuates EMT and metastatic potential in breast cancer. EMBO Mol Med 2:401–414. doi:10.1002/emmm.201000095
33. Liao Q, Kleeff J, Xiao Y, Guweidhi A, Schambony A, Töpfer-Petersen E et al (2003) Preferential expression of cystein-rich secretory protein-3 (CRISP-3) in chronic pancreatitis. Histol Histopathol 18:425–433
34. Tapinos NI, Polihronis M, Thyphronitis G, Moutsopoulos HM (2002) Characterization of the cysteine-rich secretory protein 3 gene as an early-transcribed gene with a putative role in the pathophysiology of Sjögren’s syndrome. Arthritis Rheum 46:215–222